Stryker lowers 2026 guidance after slowdown in hip, knee procedures
Stryker reported Q3 revenue of $6.5B, up 7.7% YoY, but net earnings fell 12.3% YoY. CEO Kevin Lobo cited a market slowdown in hip and knee procedures due to economic challenges. The company lowered its 2026 sales guidance to 6.5-7.0% from 8.3-9.3%. Lobo will step down as CEO at year-end, succeeded by COO Spencer Stiles. Stryker also invested $400M in CMR Surgical for U.S. distribution rights.
How this was made
The 30-second read
Why it matters
The guidance downgrade is the primary market‑moving event; analyst reactions and the CMR Surgical partnership are secondary.
Market read
Guidance cut likely triggers a sell‑off in SYK and may influence sentiment toward the broader med‑tech sector.
What to watch
Potential upside from the new CMR Surgical partnership and robotics investment.
Background
Stryker reported Q3 results showing modest revenue growth but a decline in net earnings, citing slower joint‑replacement procedures due to higher insurance costs.
Ticker impact
Stryker lowered its 2026 sales guidance to 6.5%-7.0% from 8.3%-9.3% after reporting slower hip and knee procedure volumes.
downward pressure as investors price in slower growth and lower guidance
Guidance revisions are material for a large‑cap med‑tech firm and are disclosed for the first time.
Market effects
May weigh on other orthopedics and med‑tech peers as demand slowdown could be broader.
U.S. market may see modest pullback in health‑care stocks.
Limited to U.S. med‑tech sector; no immediate global macro effect.
Counterpoint
If the slowdown is temporary, the guidance cut could be an overreaction, presenting a buying opportunity.
Key entities
- ExecutiveKevin Lobo
Stryker CEO who announced the guidance cut.
- CompanyCMR Surgical
Soft‑tissue robotics firm receiving a $400 million investment from Stryker.
